ANDA 209839, held by Cipla. Solifenacin Succinate.
As of Nov 16, 2026, ANDA 209839 (Solifenacin Succinate), held by Cipla, was first approved by FDA on May 20, 2019, with 1 approved supplement and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| May 20, 2019 | Original application | Approved | None posted |
| Solifenacin Succinate5MG · tablet;oral | Solifenacin Succinate | Discontinued |
| Solifenacin Succinate10MG · tablet;oral | Solifenacin Succinate | Discontinued |
| Nov 24, 2020 | Supplement 4Labeling · Standard review | Approved | None posted |
| May 20, 2019 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters